Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Endometrioid × temsirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 7 Sarcoma 5 Melanoma 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Lymphoma, Non-Hodgkin 4 Endometrial Neoplasms 4 Carcinoma, Hepatocellular 4 Neoplasm Metastasis 3 Multiple Myeloma 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Acute 3 Kidney Neoplasms 3 Glioblastoma 3 Squamous Cell Carcinoma of Head and Neck 2 Rhabdomyosarcoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Lymphoma, Mantle-Cell 2 Liver Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hodgkin Disease 2 Fallopian Tube Neoplasms 2 Congenital Abnormalities 2 Breast Neoplasms 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1

Interventions

Nivolumab 3 Specimen Handling 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 CTLA-4 Antigen 2 temsirolimus 1 serabelisib 1 sapanisertib 1 rucaparib 1 olaparib 1 durvalumab 1 ceralasertib 1 cabozantinib 1 Paclitaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02093598 2020-11-27

POEM

MedSIR

Phase 2 Completed

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡